Comparison of outcomes using the sirolimus-eluting stent in calcified versus non-calcified native coronary lesions in patients on- versus not on-chronic hemodialysis (from the j-Cypher registry).

The impact of lesion calcium on long-term outcomes after drug-eluting stent implantation has not been adequately addressed. In 10,595 patients (16,803 lesions) who were exclusively treated with sirolimus-eluting stents in the j-Cypher registry, 5-year outcomes were compared between patients with ≥1 lesion with moderate or severe calcification (the calcium group) and those with noncalcified lesions only (the noncalcium group). Analyses were stratified by hemodialysis (HD) status (non-HD stratum [calcium n = 3,191, noncalcium n = 6,824] and HD stratum [calcium n = 415, noncalcium n = 165]). Adjusted risk in the calcium group for death and target lesion revascularization was significant in the non-HD stratum (hazard ratio [HR] 1.34, 95% confidence interval [CI] 1.18 to 1.52, p <0.0001, and HR 1.2, 95% CI 1.07 to 1.36, p = 0.003) and the HD stratum (HR 1.4, 95% CI 1.06 to 1.86, p = 0.02, and HR 2.25, 95% CI 1.51 to 3.36, p <0.0001). Risk for definite stent thrombosis tended to be higher in the calcium group in the HD stratum (HR 5.05, 95% CI 0.66 to 38.9, p = 0.12) but not in then non-HD stratum (HR 1.16, 95% CI 0.81 to 1.67, p = 0.41). The use of rotational atherectomy in patients with severe calcification did not have a significant impact on the cumulative incidence of target lesion revascularization in the non-HD stratum (17.7% [n = 268] with vs 18.2% [n = 588] without rotational atherectomy, p = 0.68) and the HD stratum (54.7% [n = 115] with vs 51.9% [n = 118] without rotational atherectomy, p = 0.19). In conclusion, regardless of HD status, patients with calcified lesions have increased long-term risk for death and target lesion revascularization after sirolimus-eluting stent implantation.

[1]  Y. Hayashi,et al.  Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2012, Circulation.

[2]  P. Serruys,et al.  Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two‐year angiographic and three‐year clinical results from the SPIRIT II study , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  P. Fitzgerald,et al.  Intravascular ultrasound assessment of postprocedural incomplete stent apposition. , 2012, The Journal of invasive cardiology.

[4]  T. Hasegawa,et al.  Overview of Regular Dialysis Treatment in Japan (as of 31 December 2009) , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  M. Nobuyoshi,et al.  Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan , 2011, Cardiovascular intervention and therapeutics.

[6]  Gregg W Stone,et al.  Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study). , 2005, The American journal of cardiology.

[7]  Renu Virmani,et al.  Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. , 2009, Journal of the American College of Cardiology.

[8]  P. Teirstein,et al.  Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent Restenosis , 2004, Circulation.

[9]  Hiroshi Takahashi,et al.  Percutaneous coronary intervention with bare metal stent vs. drug-eluting stent in hemodialysis patients. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[10]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[11]  Seung‐Jung Park,et al.  Optical Coherence Tomographic Analysis of In-Stent Neoatherosclerosis After Drug–Eluting Stent Implantation , 2011, Circulation.

[12]  Masato Nakamura,et al.  Impact of calcification on the long-term outcomes of sirolimus-eluting stent implantation: subanalysis of the Cypher Post-Marketing Surveillance Registry. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[13]  K. Kent,et al.  Sirolimus‐eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  M. Leon,et al.  A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. , 2009, The American journal of cardiology.

[15]  K. Tanabe,et al.  Sirolimus eluting coronary stent implantation in patients on maintenance hemodialysis: the OUCH study (outcome of cypher stent inhemodialysis patients). , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[16]  Y. Hayashi,et al.  Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.

[17]  Y. Hayashi,et al.  Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.

[18]  W. Little,et al.  "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. , 2008, Journal of the American College of Cardiology.

[19]  V. Jorgetti,et al.  Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. , 2005, Kidney international.